Spots Global Cancer Trial Database for Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis
Official Title: Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor
Study ID: NCT00681551
Conditions
Study Description
Brief Summary: To verify the number of metastatic brain tumors detected in contrast-enhanced MRI, which is the primary variable, increases after an additional dose of Magnevist (SH L 451A) comparing images after an initial dose (0.1 mmol/kg) with those after an additional dose (0.1 mmol/kg, a total dose of 0.2 mmol/kg) intra-individually in patients with metastatic brain tumors. Safety was also to be assessed.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Yokohama-shi, Kanagawa, Japan
, Osaka-shi, Osaka, Japan
, Osaka-shi, Osaka, Japan
, Hamamatsu-shi, Shizuoka, Japan
, Bunkyo-ku, Tokyo, Japan
, Ota-ku, Tokyo, Japan
, Shinagawa-ku, Tokyo, Japan
, Shinjuku-ku, Tokyo, Japan
, Nakakoma-gun, Yamanashi, Japan
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
